Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 111
Filter
1.
Physiol Rep ; 9(22): e15117, 2021 11.
Article in English | MEDLINE | ID: mdl-34806344

ABSTRACT

Endometriosis is the abnormal growth of endometrial tissue. The goals of the study are: (1) Is any correlation between endometriosis pain and neurotrophins in the serum, dorsal root ganglion (DRG), and peritoneal fluid (PF) in rat models of experimental endometriosis?, (2) Possible therapeutic effects of royal jelly (RJ) on pain scores, size of endometriotic lesion, and neurotrophic factors. Forty-eight Sprague Dawley female rats weighing 205.023 ± 21.54 g were maintained in a standard condition. The rats were randomly divided into one of the six groups: Control (no intervention), Sham-1 (remove of uterine horn), RJ (administration of 200 mg/kg/day RJ for 21 days), Endometriosis (induction of endometriosis), Treatment (induction of endometriosis+administration of 200 mg/kg/day RJ for 21 days), and Sham-2 (induction of endometriosis+administration of water). Formalin test performed for pain evaluation. The levels of Brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), substance P, and calcitonin gene-related peptide (CGRP) were measured by enzyme-linked immunosorbent assay. The mean pain scores in all three phases of the formalin test were significantly increased by endometriosis induction (p < 0.05). The concentrations of BDNF, NGF, and CGRP in DRG of the endometriosis group were significantly higher than these factors in the Control, Sham-1, and RJ groups (p < 0.05). RJ could significantly (p < 0.001) decrease the mean lesion size and the mean pain score in the late phase (p < 0.05). The present results determine that endometriosis pain may be related to nervous system neurotrophic factors. Treatment with RJ could decrease the size of endometriosis lesions as well as pain scores. The findings may shed light on other complementary and alternative remedies for endometriosis.


Subject(s)
Endometriosis/metabolism , Fatty Acids/pharmacology , Nerve Growth Factors/drug effects , Animals , Ascitic Fluid/drug effects , Ascitic Fluid/metabolism , Brain-Derived Neurotrophic Factor/drug effects , Brain-Derived Neurotrophic Factor/metabolism , Calcitonin Gene-Related Peptide/drug effects , Calcitonin Gene-Related Peptide/metabolism , Disease Models, Animal , Endometriosis/pathology , Female , Ganglia, Spinal/drug effects , Ganglia, Spinal/metabolism , Nerve Growth Factor/drug effects , Nerve Growth Factor/metabolism , Nerve Growth Factors/metabolism , Pain Measurement/drug effects , Rats , Substance P/drug effects , Substance P/metabolism
2.
Regul Toxicol Pharmacol ; 122: 104916, 2021 Jun.
Article in English | MEDLINE | ID: mdl-33711392

ABSTRACT

Cizolirtine, a substance-P and calcitonin gene-related peptide release modulator developed for the treatment of pain and urinary incontinence, was orally administered for 26-weeks to rats at dosages of 20, 60 and 200 mg/kg/day. Clinical signs were limited to post-dosing salivation and brown staining on head and muzzle. There were slight decreases in bodyweight gain and slight increases in water consumption among cizolirtine-treated animals. Slight increases in plasma alkaline phosphatase activity, and cholesterol and phospholipid concentrations were observed in mid- and/or high-dose animals. Low urinary volume, pH and sodium and potassium outputs were observed after 12-weeks, and low urinary pH, low sodium and high potassium outputs at end of treatment. Increased relative (to bodyweight) liver weight was observed in high-dose animals. Treated males and high-dose females showed a dose-related increase in the incidence and severity of periacinar hepatocytic hypertrophy and midzonal/periacinar hepatocytic fat vacuolization. Increased incidences of hepatic clear cell foci were observed in all cizolirtine-treated male groups and, to a lesser extent, in treated females. Ovaries of treated females showed a dose-dependent increased incidence of absent corpora lutea and, occasionally, follicular cysts. The dosages of 20 and 60 mg/kg/day were considered as the No-Observed-Adverse-Effect Levels for males and females, respectively.


Subject(s)
Analgesics/toxicity , Calcitonin Gene-Related Peptide/drug effects , Liver/drug effects , Pyrazoles/toxicity , Substance P/drug effects , Animals , Body Weight , Dose-Response Relationship, Drug , Drinking , Female , Hydrogen-Ion Concentration , Lipids/blood , Male , Organ Size , Rats , Rats, Sprague-Dawley , Sex Factors , Water-Electrolyte Balance
3.
CNS Neurol Disord Drug Targets ; 19(5): 344-359, 2020.
Article in English | MEDLINE | ID: mdl-32552657

ABSTRACT

Migraine is a complex neurovascular disorder characterized by attacks of moderate to severe unilateral headache, accompanied by photophobia among other neurological signs. Although an arsenal of antimigraine agents is currently available in the market, not all patients respond to them. As Calcitonin Gene-Related Peptide (CGRP) plays a key role in the pathophysiology of migraine, CGRP receptor antagonists (gepants) have been developed. Unfortunately, further pharmaceutical development (for olcegepant and telcagepant) was interrupted due to pharmacokinetic issues observed during the Randomized Clinical Trials (RCT). On this basis, the use of monoclonal antibodies (mAbs; immunoglobulins) against CGRP or its receptor has recently emerged as a novel pharmacotherapy to treat migraines. RCT showed that these mAbs are effective against migraines producing fewer adverse events. Presently, the U.S. Food and Drug Administration approved four mAbs, namely: (i) erenumab; (ii) fremanezumab; (iii) galcanezumab; and (iv) eptinezumab. In general, specific antimigraine compounds exert their action in the trigeminovascular system, but the locus of action (peripheral vs. central) of the mAbs remains elusive. Since these mAbs have a molecular weight of ∼150 kDa, some studies rule out the relevance of their central actions as they seem unlikely to cross the Blood-Brain Barrier (BBB). Considering the therapeutic relevance of this new class of antimigraine compounds, the present review has attempted to summarize and discuss the current evidence on the probable sites of action of these mAbs.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Calcitonin Gene-Related Peptide Receptor Antagonists/pharmacology , Calcitonin Gene-Related Peptide/drug effects , Migraine Disorders/drug therapy , Antibodies, Monoclonal/immunology , Blood-Brain Barrier/drug effects , Blood-Brain Barrier/immunology , Calcitonin Gene-Related Peptide/immunology , Headache/drug therapy , Humans
4.
Cephalalgia ; 40(7): 650-664, 2020 06.
Article in English | MEDLINE | ID: mdl-32418458

ABSTRACT

BACKGROUND: Recently, the adenosine triphosphate (ATP) sensitive potassium channel opener levcromakalim was shown to induce migraine attacks with a far higher incidence than any previous provoking agent such as calcitonin gene-related peptide. Here, we show efficacy of ATP sensitive potassium channel inhibitors in two validated rodent models of migraine. METHODS: In female spontaneous trigeminal allodynic rats, the sensitivity of the frontal region of the head was tested by an electronic von Frey filament device. In mice, cutaneous hypersensitivity was induced by repeated glyceryl trinitrate or levcromakalim injections over nine days, as measured with von Frey filaments in the hindpaw. Release of calcitonin gene-related peptide from dura mater and trigeminal ganglion was studied ex vivo. RESULTS: The ATP sensitive potassium channel inhibitor glibenclamide attenuated the spontaneous cephalic hypersensitivity in spontaneous trigeminal allodynic rats and glyceryl trinitrate-induced hypersensitivity of the hindpaw in mice. It also inhibited CGRP release from dura mater and the trigeminal ganglion isolated from spontaneous trigeminal allodynic rats. The hypersensitivity was also diminished by the structurally different ATP sensitive potassium channel inhibitor gliquidone. Mice injected with the ATP sensitive potassium channel opener levcromakalim developed a progressive hypersensitivity that was completely blocked by glibenclamide, confirming target engagement. CONCLUSION: The results suggest that ATP sensitive potassium channel inhibitors could be novel and highly effective drugs in the treatment of migraine.


Subject(s)
Glyburide/pharmacology , KATP Channels/antagonists & inhibitors , Migraine Disorders/drug therapy , Sulfonylurea Compounds/pharmacology , Animals , Calcitonin Gene-Related Peptide/drug effects , Calcitonin Gene-Related Peptide/metabolism , Dura Mater/drug effects , Hyperalgesia/drug therapy , Mice , Mice, Inbred C57BL , Pain Threshold/drug effects , Rats , Rats, Sprague-Dawley , Trigeminal Ganglion/drug effects
5.
Headache ; 60(1): 110-123, 2020 01.
Article in English | MEDLINE | ID: mdl-31721185

ABSTRACT

OBJECTIVE: Blood pressure (BP), pulse, electrocardiogram (ECG), and clinical cardiovascular (CV) outcomes in patients with episodic or chronic migraine treated for up to 6 months with galcanezumab compared to placebo were evaluated. BACKGROUND: Calcitonin gene-related peptide, a potent microvascular vasodilator, has a hypothesized protective role in CV health. Increased CV risks have been reported in patients with migraine. METHODS: In 2 similarly designed episodic migraine 6-month studies and 1 chronic migraine 3-month study, data from patients randomized (1:1:2) to subcutaneous injection of galcanezumab 120 mg/month (following initial 240 mg loading dose) or 240 mg/month or placebo were pooled. Treatment comparisons for cardiovascular treatment-emergent adverse events (CV TEAE) and categorical and mean changes in BP, pulse, and ECG were evaluated using the Cochran-Mantel-Haenszel test. Mean changes from baseline in BP, pulse, and ECG were evaluated using the analysis of covariance model. RESULTS: Overall, among galcanezumab 120 mg (n = 705) and 240 mg (n = 730), and placebo (n = 1451) groups, the percentage of patients reporting ≥1 CV TEAE was low and was similar between the galcanezumab 120 mg (2.6%; odds ratio [OR] = 0.9; 95% confidence interval [CI]: 0.5,1.5) and galcanezumab 240 mg (3.3%; OR = 1.1; 95% CI: 0.7,1.9), and placebo (2.9%) groups. The frequency of any individual CV TEAE, broad or narrow term, was ≤1.4%. The CV-related serious adverse events that occurred in the galcanezumab 240 mg group (n = 3; acute myocardial infarction, pulmonary embolism, and transient ischemic attack) and placebo group (n = 3; pulmonary embolism, deep vein thrombosis, and myocardial infarction) were not considered treatment related. Four placebo- and 1 galcanezumab-treated patient discontinued due to a CV TEAE. Least squares mean and categorical changes from baseline in BP, pulse, and QT interval corrected using Fridericia's correction were similar across treatment groups. CONCLUSIONS: In this 6-month treatment trial, the percentages of galcanezumab- and placebo-treated patients that reported CV TEAEs or serious adverse events were low and similar between groups with few discontinuations. Thus, no clinically meaningful treatment group differences were observed for changes in BP, pulse, or ECG parameters. Additional longer-term studies in a broader and larger cohort are required to better characterize CV safety.


Subject(s)
Antibodies, Monoclonal, Humanized/administration & dosage , Antibodies, Monoclonal, Humanized/adverse effects , Blood Pressure/drug effects , Calcitonin Gene-Related Peptide/drug effects , Cardiovascular Diseases/chemically induced , Electrocardiography/drug effects , Heart Rate/drug effects , Migraine Disorders/prevention & control , Adult , Chronic Disease , Female , Humans , Male , Middle Aged , Treatment Outcome
6.
Rev Assoc Med Bras (1992) ; 65(9): 1188-1192, 2019.
Article in English | MEDLINE | ID: mdl-31618336

ABSTRACT

OBJECTIVE: We aimed to explore the effects of neuropeptides ghrelin, obestatin, and vasoactive intestinal peptide (VIP) on seizures and plasma concentrations of neuroinflammation biomarkers including calcitonin gene-related peptide (CGRP), substance-P (SP), and interleukin-1 beta (IL-1ß) in pentylenetetrazol-induced seizures in rats. METHODS: Ghrelin (80 µg/kg), obestatin (1 µg/kg), VIP (25 ng/kg) or saline were administered to rats intraperitoneally 30 min before pentylenetetrazole (PTZ, 50 mg/kg) injections. Stages of epileptic seizures were evaluated by Racine's scale, and plasma CGRP, SP, and IL-1ß concentrations were measured using ELISA. RESULTS: Both obestatin and VIP shortened onset-time of generalized tonic-clonic seizure, respectively, moreover VIP also shortened the onset-time of first myoclonic-jerk induced by PTZ. While PTZ increased plasma CGRP, SP and IL-1ß concentrations, ghrelin reduced the increases evoked by PTZ. While VIP further increased PTZ-evoked CGRP levels, it diminished IL-1ß concentrations. However, obestatin did not change CGRP, SP, and IL-1ß concentrations. CONCLUSION: Our results suggest that ghrelin acts as an anticonvulsant, obestatin acts as a proconvulsant, and VIP has dual action on epilepsy. Receptors of those neuropeptides may be promising targets for epilepsy treatment.


Subject(s)
Convulsants , Neuropeptides , Pentylenetetrazole , Peptide Hormones , Seizures , Animals , Male , Biomarkers/blood , Calcitonin Gene-Related Peptide/blood , Calcitonin Gene-Related Peptide/drug effects , Convulsants/adverse effects , Disease Models, Animal , Ghrelin/pharmacology , Inflammation , Interleukin-1beta/blood , Interleukin-1beta/drug effects , Myoclonus , Neuropeptides/drug effects , Pentylenetetrazole/adverse effects , Peptide Hormones/pharmacology , Random Allocation , Rats, Wistar , Seizures/chemically induced , Seizures/metabolism , Substance P/blood , Substance P/drug effects , Time Factors , Vasoactive Intestinal Peptide/pharmacology
7.
Headache ; 59 Suppl 2: 20-32, 2019 07.
Article in English | MEDLINE | ID: mdl-31291020

ABSTRACT

Calcitonin-gene-related peptide (CGRP), a neuropeptide broadly distributed in neuronal and non-neuronal regions throughout the body, plays a fundamental role in migraine and cluster headache (CH) pathophysiology. CGRP functional blockade alleviates neurogenic inflammation and reduces pain pathway sensitization. Two types of CGRP function-blocking modalities, monoclonal antibodies (MAbs), and small molecules (gepants), have been designed to target the CGRP ligands and CGRP receptors. In this narrative review, we summarized the latest clinical trials on gepants and CGRP function-blocking MAbs for migraine and CH prevention. At the time of writing, newer gepants are currently under Federal Drug Administration (FDA) review for migraine management, but there is no study yet on the usage of gepants for CH. Erenumab, fremanezumab, and galcanezumab have been approved by the FDA for migraine prevention while eptinezumab is under FDA review. CGRP MAbs are as effective as and more tolerable than conventional migraine preventives. For CH prevention, galcanezumab has shown some promising findings and was recently approved for use in episodic cluster prevention. CGRP function-blocking therapy not only demonstrates high efficacy and superior safety profile, but also improves headache frequency and quality of life. Convenient monthly dosing for the MAbs can further improve medication adherence, hence better headache control. With CGRP function-blocking therapy showing efficacy even in individuals who failed other preventives, it has become an exciting new therapeutic option in the field of migraine and CH.


Subject(s)
Antibodies, Monoclonal/pharmacology , Calcitonin Gene-Related Peptide Receptor Antagonists/pharmacology , Calcitonin Gene-Related Peptide/drug effects , Cluster Headache/drug therapy , Migraine Disorders/drug therapy , Humans
8.
Expert Rev Neurother ; 19(8): 719-728, 2019 08.
Article in English | MEDLINE | ID: mdl-31043094

ABSTRACT

Introduction: The importance of calcitonin gene-related peptide (CGRP) in migraine pathogenesis is well established. Fremanezumab is a humanized IgG2a monoclonal antibody that binds to CGRP. Areas covered: In this paper, we review the development of fremanezumab, from early development into approval. The authors focus on the efficacy and safety of fremanezumab in both migraine stages. The authors highlight studies conducted in special populations and focus on unique aspects of its development, as well as on clinical pearls supported by the data. Expert opinion: Fremanezumab was shown to be effective in episodic and chronic migraine, with a monthly and quarterly dose of administration, as monotherapy and add-on therapy. As with other monoclonal antibodies, the anti-CGRP onset of action was remarkably quick, and the effect seems to be maintained over time. No overt safety concerns emerged from the clinical studies, although long-term surveillance is necessary.


Subject(s)
Antibodies, Monoclonal, Humanized/pharmacology , Antibodies, Monoclonal/pharmacology , Calcitonin Gene-Related Peptide/drug effects , Chronic Disease/prevention & control , Migraine Disorders/prevention & control , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal, Humanized/adverse effects , Humans
9.
Cephalalgia ; 39(11): 1421-1434, 2019 Oct.
Article in English | MEDLINE | ID: mdl-31104506

ABSTRACT

BACKGROUND: The current understanding of mechanisms behind migraine pain has been greatly enhanced with the recent therapies targeting calcitonin gene-related peptide and its receptor. The clinical efficacy of calcitonin gene-related peptide-blocking drugs indicates that, at least in a considerable proportion of patients, calcitonin gene-related peptide is a key molecule in migraine pain. There are several receptors and molecular pathways that can affect the release of and response to calcitonin gene-related peptide. One of these could be purinergic receptors that are involved in nociception, but these are greatly understudied with respect to migraine. OBJECTIVE: We aimed to explore purinergic receptors as potential anti-migraine targets. METHODS: We used the human middle meningeal artery as a proxy for the trigeminal system to screen for possible anti-migraine candidates. The human findings were followed by intravital microscopy and calcitonin gene-related peptide release measurements in rodents. RESULTS: We show that the purinergic P2Y13 receptor fulfills all the features of a potential anti-migraine target. The P2Y13 receptor is expressed in both the human trigeminal ganglion and middle meningeal artery and activation of this receptor causes: a) middle meningeal artery contraction in vitro; b) reduced dural artery dilation following periarterial electrical stimulation in vivo and c) a reduction of CGRP release from both the dura and the trigeminal ganglion in situ. Furthermore, we show that P2X3 receptor activation of the trigeminal ganglion causes calcitonin gene-related peptide release and middle meningeal artery dilation. CONCLUSION: Both an agonist directed at the P2Y13 receptor and an antagonist of the P2X3 receptor seem to be viable potential anti-migraine therapies.


Subject(s)
Meningeal Arteries/drug effects , Migraine Disorders/metabolism , Purinergic P2 Receptor Agonists/pharmacology , Purinergic P2 Receptor Antagonists/pharmacology , Aged , Aged, 80 and over , Animals , Calcitonin Gene-Related Peptide/drug effects , Calcitonin Gene-Related Peptide/metabolism , Disease Models, Animal , Female , Humans , Male , Meningeal Arteries/metabolism , Middle Aged , Rats, Sprague-Dawley , Receptors, Purinergic P2/drug effects , Receptors, Purinergic P2/metabolism , Receptors, Purinergic P2X3/drug effects , Receptors, Purinergic P2X3/metabolism , Trigeminal Ganglion/drug effects , Trigeminal Ganglion/metabolism
10.
Handb Exp Pharmacol ; 255: 121-130, 2019.
Article in English | MEDLINE | ID: mdl-30725283

ABSTRACT

Migraine is a common neurological disorder that afflicts up to 15% of the adult population in most countries, with predominance in females. It is characterized by episodic, often disabling headache, photophobia and phonophobia, autonomic symptoms (nausea and vomiting), and in a subgroup an aura in the beginning of the attack. Although still debated, many researchers consider migraine to be a disorder in which CNS dysfunction plays a pivotal role while various parts of the trigeminal system are necessary for the expression of associated symptoms.Treatment of migraine has in recent years seen the development of drugs that target the trigeminal sensory neuropeptide calcitonin gene-related peptide (CGRP) or its receptor. Several of these drugs are now approved for use in frequent episodic and in chronic migraine. CGRP-related therapies offer considerable improvements over existing drugs, as they are the first to be designed specifically to act on the trigeminal pain system: they are more specific and have little or no adverse effects. Small molecule CGRP receptor antagonists, gepants, are effective for acute relief of migraine headache, whereas monoclonal antibodies against CGRP (Eptinezumab, Fremanezumab, and Galcanezumab) or the CGRP receptor (Erenumab) effectively prevent migraine attacks. The neurobiology of CGRP signaling is briefly summarized together with key clinical evidence for the role of CGRP in migraine headache, including the efficacy of CGRP-targeted treatments.


Subject(s)
Calcitonin Gene-Related Peptide , Migraine Disorders , Calcitonin , Calcitonin Gene-Related Peptide/drug effects , Calcitonin Gene-Related Peptide Receptor Antagonists/therapeutic use , Female , Humans , Migraine Disorders/drug therapy , Pain
11.
Neuroreport ; 30(4): 288-294, 2019 03 06.
Article in English | MEDLINE | ID: mdl-30676543

ABSTRACT

Chemotherapy-induced peripheral neuropathic pain is a major dose-limiting and therapy-limiting adverse effect that is particularly difficult to treat. Puerarin, a major active ingredient of traditional Chinese plant medicine Gegen, is commonly used in the treatment of myocardial and cerebral ischemia. However, the effects of puerarin on neuropathic pain are still unknown. Therefore, the aim of this study is to examine the effects of puerarin on neuropathic pain. In this study, the effects of puerarin were tested in-vivo on a rat model of paclitaxel-induced peripheral neuropathic pain (PIPNP). The results show that a single injection of puerarin produced short-term analgesic effect on pre-established PIPNP, as indicated by decreased mechanical allodynia and thermal hyperalgesia in comparison with paclitaxel-treated rats. Repeated doses of puerarin, given during PIPNP induction, prevented the development of PIPNP. This prophylactic effect of puerarin was associated with suppressed paclitaxel-induced transient receptor potential vanilloid 1, calcitonin gene-related peptide and substance P up-regulation in the dorsal root ganglia. These findings revealed the therapeutic potential of puerarin in treating and preventing chemotherapy-induced peripheral neuropathic pain.


Subject(s)
Antineoplastic Agents, Phytogenic/toxicity , Isoflavones/pharmacology , Neuralgia/chemically induced , Neuralgia/metabolism , Paclitaxel/toxicity , Animals , Calcitonin Gene-Related Peptide/drug effects , Calcitonin Gene-Related Peptide/metabolism , Male , Rats , Rats, Sprague-Dawley , Substance P/drug effects , Substance P/metabolism , TRPV Cation Channels/drug effects , TRPV Cation Channels/metabolism
12.
Acta Neuropsychiatr ; 31(2): 93-99, 2019 Apr.
Article in English | MEDLINE | ID: mdl-30509331

ABSTRACT

OBJECTIVE: Genetic and environmental factors interact in the development of major depressive disorder (MDD). While neurobiological correlates have only partially been elucidated, altered levels of calcitonin gene-related peptide (CGRP)-like immunoreactivity (LI) in animal models and in the cerebrospinal fluid of depressed patients were reported, suggesting that CGRP may be involved in the pathophysiology and/or be a trait marker of MDD. However, changes in CGRP brain levels resulting from interactions between genetic and environmental risk factors and the response to antidepressant treatment have not been explored. METHODS: We therefore superimposed maternal separation (MS) onto a genetic rat model (Flinders-sensitive and -resistant lines, FSL/FRL) of depression, treated these rats with antidepressants (escitalopram and nortriptyline) and measured CGRP-LI in selected brain regions. RESULTS: CGRP was elevated in the frontal cortex, hippocampus and amygdala (but not in the hypothalamus) of FSL rats. However, MS did not significantly alter levels of this peptide. Likewise, there were no significant interactions between the genetic and environmental factors. Most importantly, neither escitalopram nor nortriptyline significantly altered brain CGRP levels. CONCLUSION: Our data demonstrate that increased brain levels of CGRP are present in a well-established rat model of depression. Given that antidepressants have virtually no effect on the brain level of this peptide, our study indicates that further research is needed to evaluate the functional role of CGRP in the FSL model for depression.


Subject(s)
Antidepressive Agents/pharmacology , Brain , Calcitonin Gene-Related Peptide , Citalopram/pharmacology , Depression , Gene-Environment Interaction , Maternal Deprivation , Nortriptyline/pharmacology , Amygdala/drug effects , Amygdala/metabolism , Animals , Brain/drug effects , Brain/metabolism , Calcitonin Gene-Related Peptide/drug effects , Calcitonin Gene-Related Peptide/metabolism , Depression/drug therapy , Depression/etiology , Depression/metabolism , Disease Models, Animal , Frontal Lobe/drug effects , Frontal Lobe/metabolism , Hippocampus/drug effects , Hippocampus/metabolism , Male , Rats
13.
Dig Dis Sci ; 64(2): 447-455, 2019 02.
Article in English | MEDLINE | ID: mdl-30370491

ABSTRACT

BACKGROUND: Calcitonin gene-related peptide (CGRP) has antioxidant and anti-inflammatory activities on the pathological damage of acute pancreatitis. However, its molecular mechanism on severe acute pancreatitis (SAP) remains unknown. AIMS: To evaluate the influence of CGRP-mediated p38MAPK signaling pathway in rats with SAP. METHODS: SD rats were randomly divided into Sham group, SAP group, CGRP group (SAP rats injected with CGRP), SB203580 group (rats injected with p38MAPK pathway inhibitor SB203580), and CGRP8-37 group (SAP rats injected with CGRP8-37). Serum amylase and lipase activities were determined. Histopathological observations were evaluated, and the expression of inflammatory cytokines and oxidative stress-related indexes were measured. RESULTS: Compared with Sham group, SAP rats were increased in the activities of serum amylase and lipase, the pathologic assessment of pancreatic tissue, the levels of TNF-α, IL-1ß, IL-6, and IL-8, the content of MDA and MPO, and the expressions of CGRP, and p-p38MAPK protein, but they were decreased in SOD activity and GSH content. The above alterations were aggravated in the CGRP8-37 group when compared with SAP group. Besides, in comparison with SAP group, rats in the CGRP and SB203580 groups presented a reduction in the activities of serum amylase and lipase, the levels of inflammatory cytokines, the content of MDA and MPO, and the expressions of p-p38MAPK protein, while showed an elevation in SOD activity and GSH content. CONCLUSION: Pretreatment with CGRP alleviated oxidative stress and inflammatory response of SAP rats possibly by suppressing the activity of p38MAPK pathway, and thereby postponing the disease progression.


Subject(s)
Calcitonin Gene-Related Peptide/pharmacology , Enzyme Inhibitors/pharmacology , Imidazoles/pharmacology , Pancreas/drug effects , Pancreatitis/pathology , Peptide Fragments/pharmacology , Pyridines/pharmacology , p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors , Acute Disease , Amylases/blood , Amylases/drug effects , Animals , Calcitonin Gene-Related Peptide/drug effects , Calcitonin Gene-Related Peptide/metabolism , Cytokines/drug effects , Cytokines/immunology , Disease Progression , Inflammation , Interleukin-1beta/drug effects , Interleukin-1beta/immunology , Interleukin-6/immunology , Interleukin-8/drug effects , Interleukin-8/immunology , Lipase/blood , Lipase/drug effects , Malondialdehyde/metabolism , Oxidative Stress/drug effects , Pancreas/immunology , Pancreas/pathology , Pancreatitis/immunology , Peroxidase/drug effects , Peroxidase/metabolism , Random Allocation , Rats , Rats, Sprague-Dawley , Severity of Illness Index , Signal Transduction , Tumor Necrosis Factor-alpha/drug effects , Tumor Necrosis Factor-alpha/immunology , p38 Mitogen-Activated Protein Kinases/drug effects , p38 Mitogen-Activated Protein Kinases/metabolism
15.
Nat Rev Neurol ; 14(6): 338-350, 2018 06.
Article in English | MEDLINE | ID: mdl-29691490

ABSTRACT

Treatment of migraine is on the cusp of a new era with the development of drugs that target the trigeminal sensory neuropeptide calcitonin gene-related peptide (CGRP) or its receptor. Several of these drugs are expected to receive approval for use in migraine headache in 2018 and 2019. CGRP-related therapies offer considerable improvements over existing drugs as they are the first to be designed specifically to act on the trigeminal pain system, they are more specific and they seem to have few or no adverse effects. CGRP receptor antagonists such as ubrogepant are effective for acute relief of migraine headache, whereas monoclonal antibodies against CGRP (eptinezumab, fremanezumab and galcanezumab) or the CGRP receptor (erenumab) effectively prevent migraine attacks. As these drugs come into clinical use, we provide an overview of knowledge that has led to successful development of these drugs. We describe the biology of CGRP signalling, summarize key clinical evidence for the role of CGRP in migraine headache, including the efficacy of CGRP-targeted treatment, and synthesize what is known about the role of CGRP in the trigeminovascular system. Finally, we consider how the latest findings provide new insight into the central role of the trigeminal ganglion in the pathophysiology of migraine.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Calcitonin Gene-Related Peptide Receptor Antagonists/therapeutic use , Calcitonin Gene-Related Peptide/drug effects , Calcitonin Gene-Related Peptide/metabolism , Migraine Disorders/drug therapy , Migraine Disorders/metabolism , Receptors, Calcitonin Gene-Related Peptide/drug effects , Calcitonin Gene-Related Peptide/antagonists & inhibitors , Calcitonin Gene-Related Peptide/immunology , Humans , Receptors, Calcitonin Gene-Related Peptide/immunology
16.
Cephalalgia ; 38(11): 1716-1730, 2018 10.
Article in English | MEDLINE | ID: mdl-29237283

ABSTRACT

Background According to the neurovascular theory of migraine, activation of the trigeminovascular system contributes to the development of migraine. This study examined the effects of chronic intraperitoneal ghrelin (150 µg/kg) treatment on the development of chronic migraine induced by intermittent injection of nitroglycerin 10 mg/kg. Methods Baseline and post-drug (2 h following nitroglycerin injection) mechanical and thermal sensitivity were assessed by von Frey hair and tail immersion tests, respectively on days 1, 3, 5, 7, 9 and 11. Moreover, we investigated the effect of ghrelin treatment on nitroglycerin-induced aversive behavior by using a two-chamber conditioned place aversion paradigm. At the end of behavioral testing, on day 11, animals were sacrificed and plasma concentration of calcitonin gene-related peptide was measured using a rat-specific enzyme-linked immunosorbent assay kit. Also, real time polymerase chain reaction was used to quantify mRNA expression of calcitonin gene-related peptide and transient receptor potential vanilloid 1 in the trigeminal ganglion. Results Our results indicated that nitroglycerin activated the trigeminovascular system, which was reflected by mechanical and thermal hypersensitivity and elevation of mRNA expression of calcitonin gene-related peptide and transient receptor potential vanilloid-1, as migraine markers, and plasma calcitonin gene-related peptide levels. Moreover, chronic nitroglycerin injection induced conditioned place aversion and body weight loss. Nevertheless, ghrelin modulated nitroglycerin-triggered changes in transient receptor potential vanilloid-1 and calcitonin gene-related peptide expression, and mitigated nitroglycerin-induced hyperalgesia. Conclusion These results provide the first convincing evidence that ghrelin has a modulating effect on central sensitization induced by chronic intermittent nitroglycerin, and its antinociceptive effect may be related to a reduction of these factors in the trigeminal ganglion.


Subject(s)
Calcitonin Gene-Related Peptide/metabolism , Ghrelin/pharmacology , Hyperalgesia/metabolism , TRPV Cation Channels/metabolism , Animals , Calcitonin Gene-Related Peptide/drug effects , Hyperalgesia/chemically induced , Male , Nitroglycerin/toxicity , Rats , Rats, Wistar , TRPV Cation Channels/drug effects
17.
Mar Drugs ; 15(9)2017 Aug 30.
Article in English | MEDLINE | ID: mdl-28867800

ABSTRACT

Ciguatoxins (CTXs) are marine toxins that cause ciguatera fish poisoning, a debilitating disease dominated by sensory and neurological disturbances that include cold allodynia and various painful symptoms as well as long-lasting pruritus. Although CTXs are known as the most potent mammalian sodium channel activator toxins, the etiology of many of its neurosensory symptoms remains unresolved. We recently described that local application of 1 nM Pacific Ciguatoxin-1 (P-CTX-1) into the skin of human subjects induces a long-lasting, painful axon reflex flare and that CTXs are particularly effective in releasing calcitonin-gene related peptide (CGRP) from nerve terminals. In this study, we used mouse and rat skin preparations and enzyme-linked immunosorbent assays (ELISA) to study the molecular mechanism by which P-CTX-1 induces CGRP release. We show that P-CTX-1 induces CGRP release more effectively in mouse as compared to rat skin, exhibiting EC50 concentrations in the low nanomolar range. P-CTX-1-induced CGRP release from skin is dependent on extracellular calcium and sodium, but independent from the activation of various thermosensory transient receptor potential (TRP) ion channels. In contrast, lidocaine and tetrodotoxin (TTX) reduce CGRP release by 53-75%, with the remaining fraction involving L-type and T-type voltage-gated calcium channels (VGCC). Using transgenic mice, we revealed that the TTX-resistant voltage-gated sodium channel (VGSC) NaV1.9, but not NaV1.8 or NaV1.7 alone and the combined activation of the TTX-sensitive VGSC subtypes NaV1.7 and NaV1.1 carry the largest part of the P-CTX-1-caused CGRP release of 42% and 34%, respectively. Given the contribution of CGRP to nociceptive and itch sensing pathways, our findings contribute to a better understanding of sensory symptoms of acute and chronic ciguatera that may help in the identification of potential therapeutics.


Subject(s)
Ciguatoxins/pharmacology , NAV1.1 Voltage-Gated Sodium Channel/drug effects , NAV1.7 Voltage-Gated Sodium Channel/drug effects , NAV1.9 Voltage-Gated Sodium Channel/drug effects , Receptors, Calcitonin Gene-Related Peptide/drug effects , Animals , Calcitonin Gene-Related Peptide/drug effects , Calcium/metabolism , Ciguatera Poisoning/metabolism , Ciguatoxins/chemistry , Enzyme-Linked Immunosorbent Assay , Humans , Hyperalgesia/chemically induced , Lidocaine/pharmacology , Male , Marine Toxins/pharmacology , Membrane Potentials/drug effects , Mice , Mice, Transgenic , Rats , Tetrodotoxin/pharmacology
18.
Acta Neurol Belg ; 117(3): 677-685, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28584969

ABSTRACT

The neuropeptide calcitonin gene-related peptide (CGRP), a potent vasoactive and a marker of trigeminal inflammation, has been considered as an important mediator in various types of migraine such as pure menstrual migraine. Earlier studies have shown that CGRP can modulate the synthesis and release of other inflammatory factor including nitric oxide (NO) and interleukin-1beta (IL-1ß) from trigeminal ganglion glial cells. Exogenous melatonin protects the tissues from inflammatory damages. The goal of this study was to determine the anti-inflammatory effects of melatonin on the CGRP expression, inducible nitric oxide synthase (iNOS) activity, NO, and IL-1ß release in cultured peripheral blood mononuclear cells (PBMCs) from pure menstrual migraine patients and healthy subjects. This study was performed on 12 pure menstrual migraine patients and 12 age-and sex-matched healthy subjects. PBMCs were isolated and treated with melatonin for 12 h at pharmacological dose. Gene expression was evaluated by real-time PCR. CGRP and IL-1ß proteins in culture supernatant were determined by ELISA method. iNOS activity in PBMCs was determined by colorimetric assays. Total nitrite as an indicator of NO concentrations in the culture supernatants was measured using Griess method. We found that melatonin treatment significantly decreases mRNA expression of CGRP release, NO production, and iNOS activity in the patient groups. Taken together, it appears that melatonin reduces inflammation through decreasing CGRP level and iNOS activity in the patients with migraine; however, further studies are needed in this regard.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Calcitonin Gene-Related Peptide/metabolism , Gene Expression/drug effects , Inflammation/drug therapy , Interleukin-1beta/metabolism , Leukocytes, Mononuclear/metabolism , Melatonin/pharmacology , Menstruation Disturbances/complications , Migraine Disorders , Nitric Oxide Synthase Type II/metabolism , Nitric Oxide/metabolism , Adult , Calcitonin Gene-Related Peptide/drug effects , Cells, Cultured , Female , Humans , Interleukin-1beta/drug effects , Leukocytes, Mononuclear/drug effects , Migraine Disorders/drug therapy , Migraine Disorders/etiology , Migraine Disorders/metabolism , Nitric Oxide Synthase Type II/drug effects
19.
J. appl. oral sci ; 24(6): 597-606, Nov.-Dec. 2016. graf
Article in English | LILACS, BBO - Dentistry | ID: biblio-841153

ABSTRACT

ABSTRACT Objectives The aim of this study was to explore the effect of capsaicin on expression patterns of calcitonin gene-related peptide (CGRP) in the trigeminal ganglion (TG) and trigeminal subnucleus caudalis (Vc) following experimental tooth movement. Material and Methods Male Sprague-Dawley rats were used in this study and divided into small-dose capsaicin+force group, large-dose capsaicin+force group, saline+force group, and no force group. Closed coil springs were used to mimic orthodontic forces in all groups except for the no force group, in which springs were inactivated. Capsaicin and saline were injected into periodontal tissues. Rats were euthanized at 0 h, 12 h, 1 d, 3 d, 5 d, and 7 d following experimental tooth movement. Then, TG and Vc were obtained for immunohistochemical staining and western blotting against CGRP. Results Immunohistochemical results indicated that CGRP positive neurons were located in the TG, and CGRP immunoreactive fibers were distributed in the Vc. Immunohistochemical semiquantitative analysis and western blotting analysis demonstrated that CGRP expression levels both in TG and Vc were elevated at 12 h, 1 d, 3 d, 5 d, and 7 d in the saline + force group. However, both small-dose and large-dose capsaicin could decrease CGRP expression in TG and Vc at 1 d and 3 d following experimental tooth movement, as compared with the saline + force group. Conclusions These results suggest that capsaicin could regulate CGRP expression in TG and Vc following experimental tooth movement in rats.


Subject(s)
Animals , Male , Tooth Movement Techniques/methods , Trigeminal Caudal Nucleus/drug effects , Capsaicin/pharmacology , Calcitonin Gene-Related Peptide/drug effects , Trigeminal Ganglion/drug effects , Sensory System Agents/pharmacology , Reference Values , Time Factors , Trigeminal Caudal Nucleus/chemistry , Facial Pain , Immunohistochemistry , Sodium Chloride , Random Allocation , Calcitonin Gene-Related Peptide/analysis , Blotting, Western , Trigeminal Ganglion/chemistry , Reproducibility of Results , Rats, Sprague-Dawley
20.
Nat Med ; 22(10): 1160-1169, 2016 10.
Article in English | MEDLINE | ID: mdl-27571347

ABSTRACT

Orthopedic implants containing biodegradable magnesium have been used for fracture repair with considerable efficacy; however, the underlying mechanisms by which these implants improve fracture healing remain elusive. Here we show the formation of abundant new bone at peripheral cortical sites after intramedullary implantation of a pin containing ultrapure magnesium into the intact distal femur in rats. This response was accompanied by substantial increases of neuronal calcitonin gene-related polypeptide-α (CGRP) in both the peripheral cortex of the femur and the ipsilateral dorsal root ganglia (DRG). Surgical removal of the periosteum, capsaicin denervation of sensory nerves or knockdown in vivo of the CGRP-receptor-encoding genes Calcrl or Ramp1 substantially reversed the magnesium-induced osteogenesis that we observed in this model. Overexpression of these genes, however, enhanced magnesium-induced osteogenesis. We further found that an elevation of extracellular magnesium induces magnesium transporter 1 (MAGT1)-dependent and transient receptor potential cation channel, subfamily M, member 7 (TRPM7)-dependent magnesium entry, as well as an increase in intracellular adenosine triphosphate (ATP) and the accumulation of terminal synaptic vesicles in isolated rat DRG neurons. In isolated rat periosteum-derived stem cells, CGRP induces CALCRL- and RAMP1-dependent activation of cAMP-responsive element binding protein 1 (CREB1) and SP7 (also known as osterix), and thus enhances osteogenic differentiation of these stem cells. Furthermore, we have developed an innovative, magnesium-containing intramedullary nail that facilitates femur fracture repair in rats with ovariectomy-induced osteoporosis. Taken together, these findings reveal a previously undefined role of magnesium in promoting CGRP-mediated osteogenic differentiation, which suggests the therapeutic potential of this ion in orthopedics.


Subject(s)
Bone Nails , Calcitonin Gene-Related Peptide/drug effects , Femur/drug effects , Fracture Healing/drug effects , Magnesium/pharmacology , Neurons/drug effects , Osteogenesis/drug effects , Animals , Calcitonin Gene-Related Peptide/metabolism , Calcitonin Gene-Related Peptide/pharmacology , Calcitonin Receptor-Like Protein/genetics , Capsaicin/toxicity , Cation Transport Proteins/metabolism , Cell Differentiation/drug effects , Cyclic AMP Response Element-Binding Protein/drug effects , Cyclic AMP Response Element-Binding Protein/metabolism , Denervation , Female , Femoral Fractures , Fracture Fixation, Intramedullary , Fracture Healing/genetics , Ganglia, Spinal/cytology , Gene Knock-In Techniques , Gene Knockdown Techniques , Humans , Neurons/metabolism , Osteogenesis/genetics , Osteoporosis, Postmenopausal , Osteoporotic Fractures , Ovariectomy , Periosteum/cytology , Rats , Receptor Activity-Modifying Protein 1/genetics , Sensory System Agents/toxicity , Stem Cells , TRPM Cation Channels/metabolism , Transcription Factors/drug effects , Transcription Factors/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...